Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) disclosed that on 4 May 2026 it repurchased 120,000 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 3.42 to HKD 3.46 per share, representing a volume-weighted average cost of HKD 3.44. The total consideration amounted to HKD 0.41 million.

The repurchased shares equate to 0.0027% of Weigao Group’s 4.47 billion issued shares (excluding treasury shares) outstanding as of 30 April 2026. Following the transaction, the company’s outstanding share count fell to 4.47 billion, while treasury shares increased to 53.94 million. The total number of issued shares remains unchanged at 4.52 billion.

The purchase was executed under the share-repurchase mandate approved by shareholders on 27 May 2025, which authorises buybacks of up to 451.56 million shares. Cumulative repurchases under this mandate now stand at 47.29 million shares, equivalent to 10.47% of the company’s issued share capital at the time the mandate was granted.

In accordance with Hong Kong listing rules, Weigao Group confirmed that the buyback was duly authorised, all funds were fully paid, and regulatory requirements were satisfied. A 30-day moratorium on new share issues or sales of treasury shares is in effect until 4 June 2026.